First Patient Dosed in Phase 2 Study of PARP/Tankyrase Inhibitor 2X-121 for Metastatic Breast Cancer
26. Juni 2018 09:15 ET
|
2X Oncology, Inc.
CAMBRIDGE, Mass. and HOERSHOLM, Denmark, June 26, 2018 (GLOBE NEWSWIRE) -- Oncology Venture US Inc., Oncology Venture AB (OV:ST) (“OV”) and Medical Prognosis Institute A/S...
Oncology Venture Announces Abstracts on Three Pipeline Products Selected for 2018 ASCO Clinical Meeting
16. Mai 2018 17:00 ET
|
2X Oncology, Inc.
HOERSHOLM, Denmark and CAMBRIDGE, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Oncology Venture AB (OV:ST) (“OV” or the “Company”) announced today that three abstracts detailing clinical trials of its...
2X Oncology to Participate in Two Upcoming Investor Conferences
25. Oktober 2017 12:00 ET
|
2X Oncology, Inc.
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a precision medicine company developing targeted therapeutics to address significant unmet needs in...
2X Oncology Announces Validation of Drug Response Predictor (DRP) for its PARP Inhibitor 2X-121
09. August 2017 10:30 ET
|
2X Oncology, Inc.
CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a precision medicine company developing targeted therapeutics to address significant unmet needs in...
Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121
07. Juli 2017 08:30 ET
|
2X Oncology, Inc.
HOERSHOLM, Denmark and CAMBRIDGE, Mass., July 07, 2017 (GLOBE NEWSWIRE) -- Oncology Venture AB (“Oncology Venture”) and 2X Oncology, Inc. ("2X Oncology"), today announced that Oncology Venture has...
2X Oncology Obtains Investigational New Drug Application for 2X-111 Glutathione Enhanced PEGylated Liposomal Doxorubicin
08. Juni 2017 09:06 ET
|
2X Oncology, Inc.
CAMBRIDGE, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a precision medicine company developing targeted therapeutics to address significant unmet needs in...
2X Oncology to Present at Jefferies Global Healthcare Conference
31. Mai 2017 09:00 ET
|
2X Oncology, Inc.
CAMBRIDGE, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a company focused on developing targeted therapeutics to address significant unmet needs in women’s...
George O. Elston Named Chief Executive Officer of 2X Oncology
30. Mai 2017 12:25 ET
|
2X Oncology, Inc.
CAMBRIDGE, Mass., May 30, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a company focused on developing targeted therapeutics to address significant unmet needs in women’s...